Davis Matthew W. sold $26K of AQST

Davis Matthew W. (Chief Development Officer) sold 7,197 shares of Aquestive Therapeutics, Inc. (AQST) at $3.55 on 2026-11-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Davis Matthew W.
Published Nov 16, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AQST
Bearish
medium confidence
Mentioned
$AQST
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AQSTBearishLow
01

Why it matters

The disclosure provides transparency on insider selling activity, but it does not introduce new company fundamentals (no earnings, guidance, trial results, or regulatory decisions).

02

Market read

For AQST, this is primarily a sentiment/positioning datapoint rather than a catalyst.

03

What to watch

Traders may over-weight insider-sale optics; without accompanying operational updates, the filing is unlikely to change fundamental valuation.

Relevance 2/10Novelty 2/10Timing: SEC Form 4 filed 2026-11-16, covering a sale executed 2026-11-12.

Background

The article is an SEC Form 4 insider transaction disclosure for Aquestive Therapeutics (AQST).

Company-level read

Ticker impact

$AQSTBearishMedium confidence
Context

Aquestive Therapeutics insider Davis Matthew W., Chief Development Officer, sold 7,197 shares at $3.5468 on a 10b5-1 plan, per Form 4 filed today.

Expected impact

Shares may face slight overhead from the optics of an insider sale, but the 10b5-1 plan makes a large price reaction less likely.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure with a modest transaction size and explicit 10b5-1 pre-arrangement, which typically dampens market interpretation.

Market effects

Minimal, as this is a single-company insider transaction without new clinical, regulatory, or financial guidance.

None.

None.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • Aquestive Therapeutics, Inc.

    US-listed biotech subject of the Form 4 insider sale disclosure.

  • Davis Matthew W.

    Chief Development Officer who sold shares under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.